Cited by 2,639Extracellular vesicles in diseaseRNA Interference and Gene DeliveryNanoparticle-Based Drug Delivery

Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer

Open access
Kamerkar, Sushrut, LeBleu, Valerie S., Sugimoto, Hikaru, Yang, Sujuan, Ruivo, Carolina F., Melo, Sonia A., Lee, J. Jack, Kalluri, Raghu·2017·Nature

Abstract

The mutant form of the GTPase KRAS is a key driver of pancreatic cancer but remains a challenging therapeutic target. Exosomes are extracellular vesicles generated by all cells, and are naturally present in the blood. Here we show that enhanced retention of exosomes, compared to liposomes, in the circulation of mice is likely due to CD47-mediated protection of exosomes from phagocytosis by monocytes and macrophages. Exosomes derived from normal fibroblast-like mesenchymal cells were engineered to carry short interfering RNA or short hairpin RNA specific to oncogenic Kras G12D, a common mutation in pancreatic cancer. Compared to liposomes, the engineered exosomes (known as iExosomes) target oncogenic KRAS with an enhanced efficacy that is dependent on CD47, and is facilitated by macropinocytosis. Treatment with iExosomes suppressed cancer in multiple mouse models of pancreatic cancer and significantly increased overall survival. Our results demonstrate an approach for direct and specific targeting of oncogenic KRAS in tumours using iExosomes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature22341

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • siRNAs located on either side of the EV membrane can induce gene knockdown, indicating both routes are possible.

    “the ability of siRNAs located on either side of the EV membrane to induce gene knockdown indicates both routes are possible15,16.”

    From GAPDH controls extracellular vesicle biogenesis and enhances the therapeutic potential of EV mediated siRNA delivery to the brain (2021) · cites this paper as [15]

    The Results describe electroporating siRNA into exosomes, and the Extended Data (Figure 4) report targeting of KRASG12D expression by siRNA-loaded exosomes. The Methods also describe mixing siRNA with exosomes as a control, but the passages do not establish that siRNA on the outside of the EV membrane induced knockdown. The claim that both locations are effective is therefore not supported in full. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • Our findings have potential for rapid translation into clinic for combination trials with iExosomes or small molecular inhibitors targeting oncogenic KRAS.

    “we are confident that our findings have the potential for rapid translation into the clinic for combination trials with iExosomes46 (NCT03608631) or small molecular inhibitors targeting oncogenic KRAS.”
  • Exosomes expressing CD47 demonstrated enhanced circulation and accumulation in pancreatic tumors, effectively reducing KrasG12D mRNA levels and inhibiting tumor growth in mouse models.

    “Exosomes expressing CD47 demonstrated enhanced circulation and accumulation in pancreatic tumors, effectively reducing KrasG12D mRNA levels and inhibiting tumor growth in mouse models [96].”
  • Exosomes engineered to deliver siRNAs that downregulate mutant KRAS, known as iExosomes, are under clinical investigation for KRASG12D-mutant PDAC.

    “Exosomes are natural nanoparticles and have been engineered to deliver specific siRNAs to downregulate production of mutant KRAS (known as iExosomes) and are under clinical investigation for the treatment of KRASG12D-mutant PDAC203,204 (NCT03608631; Supplementary Table 1).”
  • Silencing mutant KRAS down-regulates activity of multiple Ras effector pathways including MAPK and PI3K.

    “Silencing mutant KRAS down-regulates the activity of multiple Ras effector pathways including the MAPK and PI3K pathways (67, 68).”

    From KRAS mutation in pancreatic cancer (2021) · cites this paper as [68]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Universidade do Porto (PT)
Corresponding author
Kalluri, Raghu
Venue
Nature
Published
2017-06
Volume
546
Issue
7659
Pages
498-503
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2624616322
Cited by
2,639
References
51
Citations by year
2026: 246 · 2025: 267 · 2024: 370 · 2023: 344 · 2022: 394 · 2021: 361 · 2020: 273 · 2019: 198 · 2018: 146 · 2017: 36 · 2013: 2
FWCI
72.79
Type
journal article
Language
en
Open access
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • National Institutes of Health (5u24ca126577-05)
  • National Cancer Institute (U24-CA-126577, R01CA213233, P30CA016672)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
exosomes, pancreatic cancer, KRAS G12D, siRNA delivery, CD47, macropinocytosis, phagocytosis, immune clearance, liposomes, extracellular vesicles, tumor targeting, gene silencing therapy
MeSH terms
Animals, Disease Models, Animal, Female, Liposomes, Monocytes, Neoplasm Metastasis, Pancreatic Neoplasms, Pinocytosis, Genetic Therapy, Survival Rate, Proto-Oncogene Proteins p21(ras), Gene Silencing, RNA, Small Interfering, Mice, CD47 Antigen, Exosomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review